TECH — BIO-TECHNE Corp
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 842023 ·
Last close
$72.39
Market Cap
$11.28B
52W High
$72.62
52W Low
$47.05
ADV30
3,356,435
Next earnings
2026-11-09
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | — | — | — | — | — | — | — |
| Dec 2025 | 295,877,000 | 191,277,000 | 54,461,000 | 38,009,000 | 2,522,699,000 | 172,879,000 | 511,710,000 |
| Sep 2025 | 286,555,000 | 188,112,000 | 47,658,000 | 38,185,000 | 2,526,148,000 | 144,962,000 | 560,334,000 |
| Jun 2025 | 316,964,000 | 198,812,000 | 116,689,000 | -17,678,000 | 2,557,868,000 | 162,186,000 | 639,060,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$294,858,000
Investing CF
$-10,727,000
Financing CF
$-226,358,000
CapEx
$-25,260,000
Dividends Paid
$-49,819,000
Buybacks
$-100,081,000
EPS Diluted TTM
$0.69
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$1,145,192,000
Inventory
$201,175,000
Receivables
$214,562,000
ST Investments
$0
EBIT TTM
$156,826,000
Pretax Income TTM
$147,141,000
Interest Exp TTM
$9,685,000
Analysts
11
Yahoo Snapshot (yfinance, live)
Total Revenue
$1,215,038,976
EBITDA
$355,054,016
Free Cash Flow
$224,372,368
Enterprise Value
$11,323,729,920
Total Cash
$264,712,000
Total Debt
$289,087,008
Shares Out
155,810,652
Trailing EPS
$1.16
Book Value
$13.32
ROE
9.0%
ROA
6.3%
Div Yield
0.44%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Jun 2025 | 1,219,635,000 | 242,804,000 | 73,400,000 | 2,557,868,000 | 639,060,000 | — | 287,556,000 |
| Jun 2024 | 1,159,060,000 | 246,401,000 | 168,105,000 | 2,703,867,000 | 635,017,000 | — | 298,981,000 |
| Jun 2023 | 1,136,702,000 | 290,998,000 | 285,263,000 | 2,638,692,000 | 672,176,000 | — | 254,393,000 |
| Jun 2022 | 1,105,599,000 | 295,828,000 | 272,051,000 | 2,294,805,000 | 593,794,000 | — | 325,272,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$2.32
Max Pain — expiry 2026-09-18
max pain strike: $65.00 · spot: $72.32 · call oi: 8,134 · put oi: 566
Expected Move to 2026-09-18:
±$1.85
(2.56%) —
implied range
$70.47 –
$74.17
· ATM straddle on $70.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| HALO | HALOZYME THERAPEUTICS, INC. | $12.33B | $108.64 | — |
| RGEN | REPLIGEN CORP | $10.25B | $181.62 | — |
| KRYS | Krystal Biotech, Inc. | $10.11B | $341.72 | — |
| KYMR | Kymera Therapeutics, Inc. | $10.07B | $121.05 | — |
| EXEL | EXELIXIS, INC. | $13.52B | $54.55 | — |
News headlines (Yahoo Finance, 1h cache)
Bio-Techne Corrects Dividend Announcement
2026-08-13 10:30 · Yahoo
Bio-Techne (NASDAQ:TECH) Surprises With Q2 CY2026 Sales
2026-08-12 11:37 · Yahoo
Bio-Techne Declares Dividend
2026-08-12 10:30 · Yahoo
Is Bio-Techne (TECH) Above Fair Value After A 44% Return?
2026-08-07 20:14 · Yahoo
Q1 Earnings Outperformers: Bio-Techne (NASDAQ:TECH) And The Rest Of The Research Tools & Consumables Stocks
2026-07-16 19:13 · Yahoo
Bio-Techne Launches Expanded R&D Systems AI-Engineered Designer Protein Portfolio
2026-07-08 10:30 · Yahoo
Investors’ Confidence in Bio-Techne Corp. (TECH) Strengthens as Headwind Eases
2026-08-06 13:57 · Yahoo
Bio-Techne's Q4 Earnings on Deck: What's in Store for the Stock?
2026-07-29 13:05 · Yahoo
1 Profitable Stock to Own for Decades and 2 We Turn Down
2026-08-24 09:29 · Yahoo
Is Bio-Rad a Buy as Digital PCR Growth Meets a Premium Valuation?
2026-08-21 14:31 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.